Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1994 2
1995 1
1996 1
1998 1
1999 2
2001 2
2002 2
2003 2
2004 1
2008 1
2009 2
2010 3
2011 1
2012 1
2013 1
2015 2
2016 5
2017 4
2018 5
2019 11
2020 6
2021 5
2022 3
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Polyserositis: a diagnostic challenge.
Losada I, González-Moreno J, Roda N, Ventayol L, Borjas Y, Domínguez FJ, Fernández-Baca V, García-Gasalla M, Payeras A. Losada I, et al. Intern Med J. 2018 Aug;48(8):982-987. doi: 10.1111/imj.13966. Intern Med J. 2018. PMID: 29761620
Clozapine-induced paralytic ileus.
Castillo-García IM, Maestro G, Puerta S, Ostos F, Nava P, Losada I. Castillo-García IM, et al. Among authors: losada i. Actas Esp Psiquiatr. 2016 Jan-Feb;44(1):44-5. Epub 2016 Jan 1. Actas Esp Psiquiatr. 2016. PMID: 26905889 Free article. No abstract available.
How do we measure adherence to anti-tuberculosis treatment?
Valencia S, León M, Losada I, Sequera VG, Fernández Quevedo M, García-Basteiro AL. Valencia S, et al. Among authors: losada i. Expert Rev Anti Infect Ther. 2017 Feb;15(2):157-165. doi: 10.1080/14787210.2017.1264270. Epub 2016 Dec 20. Expert Rev Anti Infect Ther. 2017. PMID: 27910715 Review.
Multidisciplinary approach in the management of hATTR.
Losada I, González-Moreno J, Rodriguez A, Uson M, Ripoll-Vera T, Ferrer-Nadal A, Rigo E, Andreu H, Figuerola A, Montalà JC, Descals C, Álvarez J, Vega-Mañés F, Roig A, Cisneros-Barroso E. Losada I, et al. Eur J Clin Invest. 2020 Oct;50(10):e13296. doi: 10.1111/eci.13296. Epub 2020 Aug 11. Eur J Clin Invest. 2020. PMID: 32474919 No abstract available.
[Isoniazid-induced toxic encephalopathy].
Ramos A, Portero JL, Murillas J, Losada I, Martín H. Ramos A, et al. Among authors: losada i. Rev Neurol. 1998 Jan;26(149):160. Rev Neurol. 1998. PMID: 9533225 Spanish. No abstract available.
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis.
Planté-Bordeneuve V, Gorram F, Olsson M, Anan I, Mazzeo A, Gentile L, Cisneros-Barroso E, Gonzalez-Moreno J, Losada I, Waddington-Cruz M, Pinto LF, Parman Y, Fanen P, Alarcon F, Nuel G. Planté-Bordeneuve V, et al. Among authors: losada i. Amyloid. 2023 Sep;30(3):313-320. doi: 10.1080/13506129.2023.2178891. Epub 2023 Feb 21. Amyloid. 2023. PMID: 36994840
Prevalence of Chagas disease in Latin American pregnant women in Madrid, Spain: A multicentre cross-sectional study from 2011 to 2016.
Herrero-Martínez JM, Trigo E, Navarro M, García-Alcázar D, Carrillo I, Fernández-López T, Calderón-Moreno M, Millán-Pérez R, Cuadros J, Velasco M, García-Bujalance S, Lizasoain M, Martín-Rabadán P, Pérez-Ayala A, Flores-Chávez M; Working Group on Chagas Disease of Madrid. Herrero-Martínez JM, et al. Trop Med Int Health. 2023 Dec;28(12):912-922. doi: 10.1111/tmi.13942. Epub 2023 Oct 31. Trop Med Int Health. 2023. PMID: 37905331
Significant reduction in proteinuria after treatment with tafamidis.
Ferrer-Nadal A, Ripoll T, Uson M, Figuerola A, Andreu H, Losada I, Gonzalez J, Cisneros-Barroso E, Buades J. Ferrer-Nadal A, et al. Among authors: losada i. Amyloid. 2019;26(sup1):67-68. doi: 10.1080/13506129.2019.1583186. Amyloid. 2019. PMID: 31343359 No abstract available.
Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial.
Pinazo MJ, Forsyth C, Losada I, Esteban ET, García-Rodríguez M, Villegas ML, Molina I, Crespillo-Andújar C, Gállego M, Ballart C, Ramirez JC, Aden T, Hoerauf A, Pfarr K, Vaillant M, Marques T, Fernandes J, Blum B, Ribeiro I, Sosa-Estani S, Barreira F, Gascón J; FEXI-12 Study Team. Pinazo MJ, et al. Among authors: losada i. Lancet Infect Dis. 2024 Apr;24(4):395-403. doi: 10.1016/S1473-3099(23)00651-5. Epub 2024 Jan 11. Lancet Infect Dis. 2024. PMID: 38218194 Clinical Trial.
69 results